Baxter International Inc. (NYSE:BAX) Plans $0.01 Quarterly Dividend

Baxter International Inc. (NYSE:BAX) declared a quarterly dividend on Wednesday, July 29th. Stockholders of record on Friday, August 28th will be paid a dividend of 0.01 per share by the medical instruments supplier on Thursday, October 1st. This represents a c) annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th.

Baxter International has decreased its dividend payment by an average of 0.1%per year over the last three years. Baxter International has a payout ratio of 1.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Baxter International to earn $1.96 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.0%.

Baxter International Stock Up 7.6%

NYSE:BAX opened at $26.65 on Friday. The firm has a 50-day simple moving average of $21.20 and a two-hundred day simple moving average of $19.56. Baxter International has a fifty-two week low of $15.73 and a fifty-two week high of $30.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.23 and a current ratio of 1.85. The firm has a market cap of $13.76 billion, a P/E ratio of -12.51, a P/E/G ratio of 4.00 and a beta of 0.62.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. During the same period last year, the business posted $0.59 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Analysts predict that Baxter International will post 1.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BAX shares. Zacks Research downgraded Baxter International from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Evercore cut their price target on Baxter International from $23.00 to $22.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Citigroup raised shares of Baxter International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $17.00 to $28.00 in a report on Friday. Weiss Ratings upgraded shares of Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus upped their price objective on Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $22.09.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.